Toscan, Cara E.
Jing, Duohui
Mayoh, Chelsea
Lock, Richard B.
Funding for this research was provided by:
Cancer Institute NSW (15/ECF/1-02)
Article History
Received: 27 September 2019
Revised: 5 February 2020
Accepted: 9 March 2020
First Online: 3 April 2020
Ethics approval and consent to participate
: All samples used in this manuscript were either purchased, established cell lines or patient-derived xenografts (passage ≥ 2) that had previously been established with appropriate informed consent. All patient-derived xenografts were previously established under approval of the University of New South Wales Animal Care and Ethics Committee. Cord blood was obtained from the Sydney Cord Blood Bank under approval of the Prince of Wales Hospital (Reference number HREC 08/190). All donors consent to their sample being used for research and the Sydney Cord Blood Bank is licensed by the Therapeutic Goods Administration and accredited by the Foundation for Accreditation of Cellular Therapy. The study was performed in accordance with the Declaration of Helsinki.
: This manuscript does not contain any individual person’s data in any form.
: All data generated or analysed during this study are included in this manuscript. InternalRef removed is available at the <i>British Journal of Cancer</i> website.
: The authors declare no competing interests.
: This research was supported through the Priority-driven Collaborative Cancer Research Scheme and co-funded by Cancer Australia and The Kids’ Cancer Project (Grant APP1129129). This research was also funded by the Anthony Rothe Memorial Trust, the National Health and Medical Research Council of Australia (NHMRC Fellowships APP1059804 and APP1157871 to RBL) and the Cancer Institute NSW (Early Career Fellowship 15/ECF/1-02 to D.J.). C.E.T. was funded by a Research Excellence Award from UNSW Sydney.